Namsa, a US-based medical device contract research organisation (CRO) providing comprehensive market access services, and Terumo, a global leader in medical technology, have entered into a strategic outsourcing partnership to accelerate regulatory approval and commercialisation of Terumo's product portfolio.

The global medtech industry is facing changing regulatory requirements and increasing clinical evidence requirements. Stricter requirements can increase development time, increase costs, and slow time to market. Namsa's strategic outsourcing solution and comprehensive range of in-house services (clinical, preclinical, testing, regulatory) enable medtech innovators to proactively mitigate risk, preserve capital, and create more value for stakeholders. This results in accelerated commercialisation and products that are more readily available to patients who need them most.

Terumo is based in Tokyo and operates worldwide. The company provides innovative medical solutions in more than 160 countries and regions. The extensive business portfolio ranges from vascular interventions and cardiac surgery solutions, blood transfusions and cell therapy technology, to medical products that are essential for daily clinical practice, such as transfusion systems, diabetes care and peritoneal dialysis treatments.